Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method

Until recently, the therapeutic protocol widely accepted for ablation of the thyroid remnant and for metastases of thyroid papillary carcinoma was the administration of 131I after surgery. However, at present, some data question the usefulness of such treatment in patients considered low risk. The t...

Full description

Saved in:
Bibliographic Details
Published inThyroid (New York, N.Y.) Vol. 11; no. 11; p. 1031
Main Authors Jiménez, R G, Moreno, A S, Gonzalez, E N, Simón FJL, Rodriguez, J R, Jimenez, J C, Córdoba, M H, Albertino, R V, Jimenez, R A
Format Journal Article
LanguageEnglish
Published United States 01.11.2001
Subjects
Adult
Algorithms
Carcinoma, Papillary - complications
Carcinoma, Papillary - radiotherapy
Half-Life
Humans
Iodine Radioisotopes - therapeutic use
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - therapy
Male
Radiometry
Renal Dialysis
Thyroid Neoplasms - complications
Thyroid Neoplasms - radiotherapy
Thyrotropin - blood
Online AccessGet more information

Cover

More Information
Summary:Until recently, the therapeutic protocol widely accepted for ablation of the thyroid remnant and for metastases of thyroid papillary carcinoma was the administration of 131I after surgery. However, at present, some data question the usefulness of such treatment in patients considered low risk. The treatment with radioiodine in patients suffering from end-stage renal disease (ESRD) undergoing hemodialysis requires controlled dosages and individualized administration guidelines. The need to include these patients on the waiting list for a renal transplantation, once they have overcome the disease, and the higher prevalence of thyroid carcinoma in ESRD patients makes this an increasingly significant problem. The cases reported in the literature are few and the therapeutic models followed are very difficult. In this paper we propose a therapeutic model that provides the highest thyroid ablative dosage, minimizing radiation exposure to the rest of the organs. The main difference between our protocol and that already described is the performance of daily hemodialysis during the first 5 days of treatment, as well as the administration of a dose of 131I equivalent to that administered to patients who show normal renal function.
ISSN:1050-7256
DOI:10.1089/105072501753271716